Having trouble viewing this email? View in your browser.

As part of our ECCMID 2024 programme, we will be hosting an influenza integrated symposium, exploring how seasonal influenza vaccines are updated and rolled out in the real world, as well as an innovation and pipeline theatre session on the scientific advancements supporting population-wide protection from infectious disease.

We look forward to you joining us in Barcelona or online through the
ECCMID integrated platform!

Our expert international faculty will take you on a journey through the development, production and implementation of seasonal influenza vaccination programmes.

Natasha Halasa,

ESCMID-appointed chairperson,
Craig Weaver Professor of Pediatrics,
Vanderbilt University, Nashville, US

Lauren Parker,

Scientific and Technical Lead,
AstraZeneca, UK

Jaime Jesús Pérez-Martín,

Senior Technician of Public Health,
Murcia Region, Spain

George Kassianos,

National Immunisation Lead,
Royal College of General
Practitioners, UK

Rosalind Hollingsworth, PhD
Global Medical Affairs Head,
Vaccines and Immune Therapies,
AstraZeneca, US
This short session will explore how vaccines and monoclonal antibodies can provide a complementary approach to the prevention of infectious diseases,
offering protection throughout life.
Learn more about AstraZeneca's commitment to reducing the global burden of infectious diseases through the development of transformative technologies.

These sessions are organised and funded by AstraZeneca.

The information displayed during the meeting is exclusively for healthcare professionals empowered to prescribe or dispense medicinal products. Please do not distribute in media, supporting materials or communication channels aimed at the general public.

La información mostrada durante la reunión está dirigida exclusivamente a Profesionales Sanitarios facultados para prescribir o dispensar medicamentos.

Por favor no distribuir en medios, soportes o canales de comunicación dirigidos a público general.

Vault ID: ES-29761; Date of approval: April 2024.

©2024 AstraZeneca Global UK. 1 Francis Crick Avenue, Cambridge,
Cambridgeshire CB2 0RE, United Kingdom. All rights reserved.

You have received this email as a contact of ESCMID or one of its affiliated societies.
You can unsubscribe here.